Table 3 Adjusted HRa and 95% CI for associations between body weight change, and oesophageal and gastric cardia adenocarcinoma incidence, NIH-AARP Diet and Health Study, and PLCO Cancer Screening Trial

From: Body weight trajectories and risk of oesophageal and gastric cardia adenocarcinomas: a pooled analysis of NIH-AARP and PLCO Studies

   Oesophageal adenocarcinoma Gastric cardia adenocarcinoma
Weight change, kg Non-cases ( n) Cases ( n) HR (95% CI) Cases ( n) HR (95% CI)
Age 20–50
−2 22 786 16 0.65 (0.38, 1.11) 15 0.95 (0.54, 1.69)
>−2 to <5 75 150 86 Referent 53 Referent
5 to <15 160 521 235 1.06 (0.83, 1.36) 158 1.17 (0.86, 1.61)
15 133 708 267 1.26 (0.98, 1.62) 159 1.23 (0.90, 1.70)
20b 80 714 171 1.35 (1.03, 1.76) 105 1.36 (0.97, 1.91)
Continuous, kg    1.01 (1.00, 1.02)   1.01 (1.00, 1.02)
P for trend    0.006   0.05
Age 20 to baseline
−2 21 169 20 1.11 (0.65, 1.89) 15 1.07 (0.58, 1.97)
>−2 to <5 51 448 43 Referent 33 Referent
5 to <15 127 569 170 1.43 (1.02, 2.00) 136 1.49 (1.02, 2.17)
15 191 979 371 1.84 (1.34, 2.54) 201 1.28 (0.88, 1.85)
20b 133 786 277 1.97 (1.43, 2.73) 155 1.40 (0.96, 2.05)
Continuous, kg    1.02 (1.01, 1.02)   1.01 (1.01, 1.02)
P for trend    <0.0001   0.0004
Age 50 to baseline
−2 61 256 80 0.79 (0.61, 1.01) 52 0.82 (0.60, 1.11)
>−2 to <5 201 027 287 Referent 185 Referent
5 to <15 101 680 176 1.16 (0.96, 1.40) 103 1.05 (0.82, 1.34)
15 28 202 61 1.57 (1.19, 2.08) 45 1.75 (1.25, 2.43)
20b 13 740 26 1.45 (0.97, 2.18) 20 1.66 (1.04, 2.65)
Continuous, kg    1.02 (1.01, 1.03)   1.02 (1.01, 1.03)
P for trend    <0.0001   0.002
Adjusted for average weight (kg)
Age 20–50
−2 22 786 16 0.56 (0.33, 0.95) 15 0.84 (0.47, 1.50)
>−2 to <5 75 150 86 Referent 53 Referent
5 to <15 160 521 235 1.07 (0.83, 1.37) 158 1.17 (0.86, 1.60)
15 133 708 267 1.16 (0.90, 1.49) 159 1.14 (0.83, 1.57)
20b 80 714 171 1.19 (0.91, 1.55) 105 1.22 (0.86, 1.72)
Continuous, kg    1.01 (1.00, 1.01)   1.01 (1.00, 1.02)
P for trend    0.1   0.2
Age 20 to baseline
−2 21 169 20 0.96 (0.56, 1.64) 15 0.93 (0.50, 1.72)
>−2 to <5 51 448 43 Referent 33 Referent
5 to <15 127 569 170 1.42 (1.02, 1.99) 136 1.48 (1.01, 2.16)
15 191 979 371 1.63 (1.18, 2.24) 201 1.12 (0.77, 1.63)
20b 133 786 277 1.68 (1.21, 2.33) 155 1.19 (0.81, 1.76)
Continuous, kg    1.01 (1.00, 1.01)   1.01 (1.00, 1.02)
P for trend    0.007   0.05
Age 50 to baseline
−2 61 256 80 0.73 (0.57, 0.94) 52 0.77 (0.56, 1.05)
>−2 to <5 201 027 287 Referent 185 Referent
5 to <15 101 680 176 1.04 (0.86, 1.26) 103 0.96 (0.75, 1.23)
15 28 202 61 1.15 (0.86, 1.55) 45 1.36 (0.96, 1.94)
20b 13 740 26 0.98 (0.64, 1.49) 20 1.22 (0.75, 1.98)
Continuous, kg    1.01 (1.00, 1.02)   1.01 (1.00, 1.02)
P for trend    0.005   0.05
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  2. aAdjusted for sex, race (non-Hispanic white, non-Hispanic black, other), smoking (never/current/former, and categorised cigarettes per day (0, 1–10, 11–20, 21–30, 31–40, 41–60, 61+)), education (high school or less, technical school or some college, college graduate, postgraduate), study, and height (m).
  3. bEstimated from a model where this was considered as a distinct category.